Enliven Therapeutics, Inc. Common Stock (ELVN) Stock
Fundamentals
Source: third-party data provider, as of October 13, 2026
Compare with ELVN
Recent news

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
ELVN

What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
ELVN

ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development
ELVN

ELVN Stock Climbs As Guggenheim Launches Coverage With $80 Price Target Ahead Of Conference Data Unveil
ELVN Stock Climbs As Guggenheim Launches Coverage With $80 Price Target Ahead Of Conference Data Unveil
ELVN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 23.55
- MACD 12/26/9
- -3.52
- EMA 9 of MACD
- -3.18
- MACD histogram
- -0.34
- SMA 50
- $53.71
- Price below SMA 50
- EMA 50
- $49.80
- Price below EMA 50
- SMA 200
- $41.17
- Price below SMA 200
- EMA 200
- $40.70
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 12, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 8 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
ELVN

What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
ELVN

ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development
ELVN

ELVN Stock Climbs As Guggenheim Launches Coverage With $80 Price Target Ahead Of Conference Data Unveil
ELVN Stock Climbs As Guggenheim Launches Coverage With $80 Price Target Ahead Of Conference Data Unveil
ELVN

Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million
ELVN

Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio
Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio
ELVN

Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k
ELVN

S&P 500, Nasdaq Futures Waver Ahead Of Supreme Court Ruling On Trump Tariffs: Why OPEN, ACON, FLYX, OSCR Are Trending After-Hours
S&P 500, Nasdaq Futures Waver Ahead Of Supreme Court Ruling On Trump Tariffs: Why OPEN, ACON, FLYX, OSCR Are Trending After-Hours
ELVN

ELVN Stock Shot Up 60% Today – What’s Driving The Rally?
ELVN Stock Shot Up 60% Today – What’s Driving The Rally?
ELVN

Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade
ELVN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Enliven Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Richard A. Fair M.B.A. | CEO, President & Director | 1969 |
| Mr. Samuel S. Kintz M.B.A. | Co-Founder & Head of Pipeline | 1986 |
| Mr. Benjamin Hohl | CFO & Head of Corporate Development | 1989 |
| Dr. Helen Louise Collins M.D. | Chief Medical Officer | 1963 |
| Dr. Joseph P. Lyssikatos Ph.D. | Co-Founder & Research Fellow | 1965 |
| Mr. Anish Patel Pharm.D. | Co-Founder & COO | 1981 |
| Dr. Galya D. Blachman Esq., Ph.D. | Chief Legal Officer & Head of Business Development | 1977 |
| Damiette Smit | Vice President of Clinical Development | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 13, 2026
Technical indicators
- RSI 14
- 23.55
- MACD 12/26/9
- -3.52
- EMA 9 of MACD
- -3.18
- MACD histogram
- -0.34
- SMA 50
- $53.71
- Price below SMA 50
- EMA 50
- $49.80
- Price below EMA 50
- SMA 200
- $41.17
- Price below SMA 200
- EMA 200
- $40.70
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 12, 2026. Technical data, not a recommendation.
Analyst views
8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $70.00
- Average
- $76.57
- High
- $82.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | -9.3 | +1.3 | -14.0 | -5.2 | +2.5 | +0.1 | -18.0 | -16.7 | -9.4 | -5.1 | +19.4 | |
| 2024 | +5.4 | -2.9 | +5.5 | -8.0 | +24.7 | +11.0 | +16.2 | -11.4 | +15.0 | +7.1 | -11.8 | -7.9 |
| 2025 | -8.5 | -4.9 | +0.3 | +0.3 | -10.5 | +4.8 | -4.3 | +8.2 | -2.0 | +18.1 | +8.0 | -22.4 |
| 2026 | +70.2 | +5.4 | +32.9 | +9.1 | -5.1 | +35.3 | +12.4 | -0.3 | -20.8 | -11.6 |



